Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CTXCVE:HEMNASDAQ:IMVCVE:MPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.49-1.0%C$0.52C$0.45▼C$0.69C$8.93M1.6915,450 shs41,000 shsHEMHemostemixC$0.15+3.6%C$0.12C$0.04▼C$0.43C$21.13M0.2410,539 shs24,588 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsMPHMedicureC$1.23-1.6%C$1.05C$0.63▼C$1.27C$12.84M0.94,035 shs4,050 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%-2.02%+3.19%-10.19%-4.90%HEMHemostemix0.00%+3.70%+21.74%+40.00%+180.00%IMVIMV0.00%0.00%0.00%0.00%0.00%MPHMedicure0.00%0.00%+6.84%+92.31%+6.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXCrescita TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXCrescita Therapeutics 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/AIMVIMV 0.00N/AN/AN/AMPHMedicure 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXCrescita TherapeuticsC$16.62M0.54C$0.40 per share1.20C$0.83 per share0.58HEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/AIMVIMV$330K0.00N/AN/A($0.69) per share0.00MPHMedicureC$21.08M0.61C$0.49 per share2.49C$1.91 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXCrescita Therapeutics-C$2.61M-C$0.15N/A∞N/A-15.73%-15.60%-8.26%N/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/AIMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AMPHMedicure-C$2.03M-C$0.19N/A∞N/A-9.65%-10.18%-5.63%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXCrescita TherapeuticsN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AMPHMedicureN/A2.24%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXCrescita Therapeutics5.772.702.29HEMHemostemix-55.070.040.48IMVIMVN/A2.932.93MPHMedicure4.652.031.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXCrescita TherapeuticsN/AHEMHemostemixN/AIMVIMV15.37%MPHMedicure23.10%Insider OwnershipCompanyInsider OwnershipCTXCrescita Therapeutics10.87%HEMHemostemix10.43%IMVIMV0.33%MPHMedicure26.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXCrescita Therapeutics6218.41 millionN/ANot OptionableHEMHemostemixN/A145.73 millionN/ANot OptionableIMVIMV9711.71 million11.67 millionOptionableMPHMedicureN/A10.44 millionN/ANot OptionableIMV, CTX, MPH, and HEM HeadlinesRecent News About These CompaniesMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia PharmacyJune 17, 2025 | finanznachrichten.deEarnings call transcript: Medicure reports Q1 2025 decline in revenue, steady stockMay 24, 2025 | uk.investing.comMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical PharmacyMarch 11, 2025 | finanznachrichten.deTyreek Hill was driving an estimated 60 mph in a 40 mph zone before hectic detainment incidentSeptember 12, 2024 | nypost.comNMedicure Inc. (NGQ1.F)August 21, 2024 | uk.finance.yahoo.comMedicure Inc. (MPH.V)August 12, 2024 | ca.finance.yahoo.comMPH:CA Medicure Inc.July 26, 2024 | seekingalpha.comPublic Health (Health Services Administration) MPHMay 25, 2024 | buffalo.eduBMaster of Public Health in Social and Behavioral SciencesMay 12, 2024 | uml.eduURochester, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 5, 2024 | yahoo.comCluj-Napoca, Romania - Weather Forecasts | Maps | News - Yahoo WeatherApril 24, 2024 | yahoo.comMedicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO DeficiencyApril 23, 2024 | finanznachrichten.deLiverpool, United Kingdom - Weather Forecasts | Maps | News - Yahoo WeatherApril 22, 2024 | yahoo.comSofia, Bulgaria - Weather Forecasts | Maps | News - Yahoo WeatherApril 21, 2024 | yahoo.comDallas, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 19, 2024 | yahoo.comPrescott, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 18, 2024 | yahoo.comPortland, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 11, 2024 | yahoo.comOttawa, Canada - Weather Forecasts | Maps | News - Yahoo WeatherApril 11, 2024 | yahoo.comFastest Cars In The World RankedApril 10, 2024 | topspeed.comTOlathe, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 8, 2024 | yahoo.comMedia Sentiment Over TimeIMV, CTX, MPH, and HEM Company DescriptionsCrescita Therapeutics TSE:CTXC$0.48 -0.01 (-1.02%) As of 01:30 PM EasternCrescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.Hemostemix CVE:HEMC$0.14 +0.01 (+3.57%) As of 02:57 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.IMV NASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Medicure CVE:MPHC$1.23 -0.02 (-1.60%) As of 01:37 PM EasternMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
